Bioinformatics Scientist I

Job Location
One MedImmune Way
Gaithersburg, MD 20854
Job Description

We are looking for an exceptional bioinformatics scientist with expertise in translational research to help with understanding of disease heterogeneity and identify predictive biomarkers with the ultimate goal of developing targeted therapies. The candidate is expected to be able to integrate multi modal multi analyze biomarker data from preclinical studies and clinical trials as well as literature based evidence to understand disease pathogenesis and progression, drug MOA and response to therapies. The job involves leveraging flow cytometry, proteomics, microarray, and next-generation sequencing technologies and bioinformatics analysis toward the identification and development of new pharmacodynamics and predictive biomarkers for the indications of inflammation and autoimmune diseases. Team work skills will be essential to work closely with biologists, external collaborators and CROs to design the right experiments and develop testable hypotheses.


Working experience in proteomics, genomics, and clinical data analysis and biological interpretation.Knowledge in state-of-art analysis methods for microarray and next-generation sequencing data.
Proficiency using R and Bioconductor packages, scripting languages, open-source and commercial bioinformatics applications.
Familiarity with biostatistics and machine learning algorithms.
Strong combination of biology and computational background.
Ability to interact in a cross-functional environment with strong oral and written skills.
Strong publication record with proven ability to lead writing of manuscripts. Education:
PhD in biological sciences, computational biology, bioinformatics, or relevant field.2-5yrs relevant experience either out of industry or academia.

About Our Organization

MedImmune is a vertically integrated biotechnology company, headquartered in Gaithersburg, Maryland and wholly owned by AstraZeneca. The company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. 

Clearly positioned among the world's leading biotechnology companies, MedImmune has leveraged its own organic growth, and has also expanded through the key acquisitions of U.S. Bioscience in 1999 and Aviron in 2002, as well as the integration with Cambridge Antibody Technology and the strategic alignment with our new parent company, AstraZeneca, in 2007. Our rapid expansion is also attributable to the activities of our business development department, responsible for actions such as strategic in-licensing, and to the launch of MedImmune Ventures Inc., a wholly-owned capital venture fund.

At Nature, Johns Hopkins' Gundula Bosch describes her graduate program that aims to get doctoral students thinking about the big picture.

Patricia Fara writes about childcare funding, and women in science and science history at NPR.

National Institute of Environmental Health Sciences researchers have visualized the career paths of former postdocs.

A new survey from the Pew Research Center finds that half of women working in STEM have experienced gender discrimination at work.